Evidence map›Paper›PMID 22113619›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2012

18F-FDG PET/CT for detection and localization of residual or recurrent disease in patients with multiple myeloma after stem cell transplantation.

Thorsten Derlin, Christoph Weber, Christian R Habermann, Jochen Herrmann, Christian Wisotzki, Francis Ayuk, Christine Wolschke, Susanne Klutmann, Nicolaus Kröger

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Review
  6. Review
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Diagnostic performance ofJapanese journal of radiology · 2018
    Article
  13. Review
  14. Article
  15. Nuclear medicine imaging of multiple myeloma, particularly in the relapsed setting.European journal of nuclear medicine and molecular imaging · 2017
    Review
  16. Treatment response evaluation withEuropean journal of nuclear medicine and molecular imaging · 2017
    Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Thorsten DerlinDepartment of Nuclear Medicine, University Medical Center Hamburg-Eppendorf, Hamburg, Germany. t.derlin@uke.uni-hamburg.de
Christoph Weber
Christian R Habermann
Jochen Herrmann
Christian Wisotzki
Francis Ayuk
Christine Wolschke
Susanne Klutmann
Nicolaus Kröger

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThe aim of the study was to determine the diagnostic performance of (18)F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/CT for the detection and localization of residual or recurrent disease in patients with multiple myeloma (MM) after stem cell transplantation.

methodsA total of 197 whole-body (18)F-FDG PET/CT scans were performed in 99 patients with MM at different time points in the course of disease after autologous or allogeneic stem cell transplantation. Post-transplant PET/CT scans and clinical remission status as determined by the clinical gold standard (Uniform Response Criteria) were analysed and compared.

resultsA total of 576 focal osseous and extramedullary lesions were detected in 79 scans. Additional diffuse bone marrow involvement was detected in 17 patients. (18)F-FDG PET/CT had a sensitivity of 54.6%, a specificity of 82.1%, a positive predictive value of 82.3%, a negative predictive value of 54.2% and an overall accuracy of 65.5%. The sensitivity of (18)F-FDG PET/CT was shown to depend on the disease category according to the Uniform Response Criteria for myeloma.

conclusionIn patients with MM in the post-transplant setting, (18)F-FDG PET/CT may (1) contribute to the detection and localization of disease, (2) provide information about the extent of distinct myeloma manifestations and the total disease burden and (3) add information about the metabolic activity of disease, but (4) has substantially lower sensitivity for this purpose compared to the pretreatment setting.

Indexed as

Fluorodeoxyglucose F18Multimodal ImagingPositron-Emission TomographyStem Cell TransplantationTomography, X-Ray ComputedAdultAgedFemaleHumansMaleMiddle AgedMultiple MyelomaNeoplasm, ResidualRecurrenceReference StandardsReproducibility of ResultsFluorodeoxyglucose F18

Identifiers

PMID22113619

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.